Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Ann Surg. 2022 Jun 1;275(6):1043-1049. doi: 10.1097/SLA.0000000000005430. Epub 2022 Mar 3.
Ann Surg. 2022.
PMID: 35258510
Clinical Trial.